entertainment -WSS

entertainment

author：comprehensive 2025-10-03 01:03:05 - browse：33

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Change Healthcare outage fallout shows need for new oversight

focus

WSS

First U.S. drug developed to treat liver disease MASH is approved

Biotech startup Celsius cuts 75% of staff ahead of first trial start

WuXi out of biotech trade group, U.S. and China relations to blame

Ebola: Gilead Sciences antiviral shows promise as new treatment

Biotech startup Celsius cuts 75% of staff ahead of first trial start

'Null' research findings aren't empty of meaning. Let's publish them

explore

entertainment

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

UCLA team creates talking throat patch for voice disorders

Apple is now the first public company to be valued at $3 trillion

Pushing for an NIH office for post

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

President Biden's budget: Here's what you might have missed

FDA approval of Sarepta Duchenne genetic therapy gives me hope

When waiting feels immoral: Empathy in the emergency department

Medical records are filled with copy

Alnylam reports growth in sales of rare disease treatments

hotspot

How to ethically and practically extend health care to all

Pharma showers House GOP doctor with campaign cash

Why depression after traumatic brain injury is distinct

RaDonda Vaught links Vanderbilt hospital issues to patient death

WuXi out of biotech trade group, U.S. and China relations to blame

UCLA team creates talking throat patch for voice disorders

focus

explore

entertainment

Wikipedia